KRS Capital Management LLC Makes New $202,000 Investment in Edwards Lifesciences Corporation $EW

KRS Capital Management LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,585 shares of the medical research company’s stock, valued at approximately $202,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Arlington Trust Co LLC raised its holdings in Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after purchasing an additional 135 shares during the period. Valeo Financial Advisors LLC raised its holdings in shares of Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after acquiring an additional 142 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after acquiring an additional 145 shares during the period. Dakota Wealth Management raised its holdings in shares of Edwards Lifesciences by 2.5% during the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after acquiring an additional 146 shares during the period. Finally, Leo Wealth LLC raised its holdings in shares of Edwards Lifesciences by 1.2% during the first quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after acquiring an additional 150 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $75.17 on Friday. The firm has a 50-day moving average of $78.20 and a 200-day moving average of $76.08. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The company has a market cap of $44.13 billion, a PE ratio of 10.82, a price-to-earnings-growth ratio of 3.64 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.70 EPS. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of research analyst reports. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Finally, Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.06.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.